Human Clinical Trial Equipment & Supplies

Based on positive results from the preclinical research, we are ready to move forward with a clinical trial to see how well it works in humans. Clinical trials happen in several phases during which different questions are asked. Each phase builds on the results of previous ...

Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic ...

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor – 1 or SDF-1 protein. ...

Progress so far: We are currently studying BEN-2293 in a Phase I/II proof-of-concept, randomised, first-in-human clinical trial in adult patients with mild to moderate ...

Since the initial publication in 2007, CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 200 human subjects across several clinical trials. CAP-1002 consists of allogeneic “off-the-shelf” cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has ...

Microencapsulated iron salt, High concentration (40% iron), High stability and no metallic taste, Reduced gastrointestinal side effects, High bioavailability confirmed by human clinical study, Approved health claims in Europe. Daily intake of iron is essential to avoid iron deficiency, the most prevalent nutritional deficiency. Iron deficiency or low iron levels ...

Our Rare Treatment Accelerator helps academic, patient, and industry groups advance their rare disease drug redevelopment projects. By combining our team, expertise and financial resources with your research and insights, we can get treatments to patients ...

TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies, and ...

Our Vaxxine Platform is designed to harness the immune system to convert the body into its own natural “drug factory” stimulating the production of antibodies. Our technology uses synthetic peptides to mimic and optimally combine biological epitopes to selectively activate the immune system and overcome “immune tolerance”, or the body’s tendency to avoid attacking ...

Our lead compound, known as OLX07010, is a small molecule inhibitor of tau self-association which has demonstrated in vivo efficacy in two transgenic mouse models of tauopathy, htau and JNPL3, representing tau aggregation in AD and inherited tauopathies, respectively. ...

IVX-411 targets SARS-CoV-2, the coronavirus that causes COVID-19. Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly ...

Introducing BioAstin® Water-Dispersible 1% and 2% Astaxanthin Powder. Formulate with BioAstin, the #1 brand of astaxanthin in the USA! Natural Astaxanthin has proven health benefits for the body. Step your liquid game up a level by formulating with BioAstin's free-flowing, water dispersible powder, containing natural astaxanthin from ...

Loss of nerve function can be catastrophic. As many as 80% of prostate surgeries result in incontinence or erectile dysfunction because of nerve damage, and as many as 25% of head and neck surgeries damage the facial nerves. The mission of Alume Biosciences is to make our proprietary nerve illumination technology available for surgeons so that patients everywhere can benefit. Learn how you can ...

According to data from eye banks and government health agencies, less than 150,000 corneal transplants are done annually worldwide due to a shortage of human cadaver corneas. ...

The cornerstone of Cytex technology is our patented approach to producing 3-Dimensional woven implants that mimic the natural function and performance of the cartilage that lines joints such as the hip, shoulder and knee. Cytex implants can be made to fit the complex curvature found in joints, thereby helping restore and maintain natural joint ...

Emergex are developing an extensive range of CD8+ T cell adaptive vaccine candidates using two proprietary technologies designed to elicit a broad and long-lasting cellular immune response effective against an entire family of viruses and possible variants of concern, enabling robust protection against some of the world’s most impactful ...

Interleukin 7 is also known as IL7, IL-7, and is a hematopoietic growth factor secreted by stromal cells in the red marrow and thymus. It is also produced by keratinocytes, dendritic cells, hepatocytes, neurons, and epithelial cells, but is not produced by lymphocytes. IL-7 stimulates the differentiation of multipotent (pluripotent) hematopoietic stem cells into lymphoid progenitor cells, It also ...

InnoSlim® is a pharmaceutical-grade glucose and lipid metabolic regulator through activation of the adiponectin and AMPK signaling ...

A safe and accurate way of measuring the concentration of various gases at the source of production in the gastrointestinal tract (GI tract) in ...

INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the ...